Pluristem Therapeutics Inc. — Form 10-Q Summary
Period: The filing covers the quarter and nine months ended March 31, 2016 (fiscal 2016 Q3), not 2015 Q3 as stated in the request metadata. Financial statements are unaudited and amounts below are in U.S. dollars.
Business context
Pluristem is a development-stage biotherapeutics company developing placenta-derived, off-the-shelf cell therapies for ischemic and inflammatory conditions. It reported no product sales and expects continued operating losses while it funds research, clinical trials, and manufacturing.
Financial performance
| Metric | Three months ended March 31, 2016 | Nine months ended March 31, 2016 | Comparable 2015 periods |
|---|---|---|---|
| Revenue | $0 | $2.847 million | $0.095 million; $0.285 million |
| Gross profit | $0 | $2.747 million | $0.092 million; $0.275 million |
| Net loss | $7.203 million | $17.041 million | $7.226 million; $19.382 million |
| Basic and diluted loss per share | $0.09 | $0.21 | $0.10; $0.28 |
| Net R&D expense | $5.756 million | $15.221 million | $6.094 million; $15.010 million |
| General and administrative expense | $1.639 million | $4.672 million | $1.527 million; $4.718 million |
The $2.847 million nine-month revenue was recognized after United Therapeutics terminated its license agreement; Pluristem recorded the remaining upfront payment because it had no further obligations. It is not recurring product revenue. The filing reports no quarterly revenue and does not provide a meaningful ongoing product gross margin.
For the nine months, operating cash use was $12.978 million, investing cash use was $5.051 million, and financing provided $0.807 million. Cash and cash equivalents fell to $5.404 million from $22.626 million at June 30, 2015. At March 31, current assets were $39.127 million, including $11.258 million of short-term bank deposits and $20.768 million of marketable securities; current liabilities were $4.808 million, yielding working capital of $34.319 million. Stockholders’ equity was $43.106 million and accumulated deficit was $155.552 million. No conventional borrowings are reported on the balance sheet.
Changes and notable items
- Nine-month net loss improved by $2.341 million year over year, primarily because of the United agreement termination revenue. Quarterly net loss was nearly unchanged.
- Nine-month net R&D expense rose 1% as lower Israeli Office of the Chief Scientist (OCS) participation offset savings in materials, production overhead, and stock-based compensation. Quarterly net R&D expense declined 6%.
- Cash and cash equivalents declined $17.222 million from June 30, 2015. Investing cash flow shifted from $18.674 million provided in the prior-year period to $5.051 million used, reflecting deposits, securities, and property and equipment investments.
- In May 2016, after quarter-end, the subsidiary received approval for an approximately $3.3 million OCS grant for 2016 R&D; it is not included in the March 31 statements and is subject to royalty repayment terms.
- Shares outstanding were 80.080 million at March 31, 2016 and 80.162 million at May 2, 2016. The company also disclosed a $200 million shelf registration and an earlier $17 million offering closed in June 2015.
Outlook, risks, and contingencies
- Management said existing cash was sufficient to fund operations for at least the next 12 months, but also stated cash needs would increase and additional funding might be needed. Funding sources may include equity sales, grants, licensing payments, or marketable-security sales.
- Pluristem does not expect product-sale revenue in the next 12 months; near- and medium-term licensing revenue, if any, is expected to be unlikely to exceed operating costs.
- Management targeted initiating Japan CLI studies during calendar 2016, aiming for initial approval in 2018, and expected to complete enrollment in its Phase II intermittent claudication trial in the coming months. These are forward-looking plans, not assured outcomes.
- Following United’s termination of the PAH license, Pluristem regained the rights, clinical data, and regulatory submissions and planned to assess next steps, including possible licensing partners.
- Risks include clinical and regulatory uncertainty, continued operating losses and funding needs, and foreign-exchange exposure. OCS grants carry contingent royalties generally of 3%–4% on qualifying future product or service sales; the disclosed unpaid grant balance was approximately $21.017 million before interest.
- The filing reports no off-balance-sheet arrangements and states that disclosure controls were effective, with no material change in internal control over financial reporting during the quarter.
Investor verification priorities
- Confirm the timing and cash implications of the United agreement termination and whether any future PAH licensing or development plans emerged.
- Track cash burn and the composition and liquidity of deposits and marketable securities; distinguish cash equivalents from other current financial assets.
- Verify receipt and terms of the approximately $3.3 million OCS grant, including its royalty obligations.
- Monitor clinical-trial enrollment, study starts, regulatory milestones, and whether stated timelines remain achievable.
- Assess potential dilution from future financing under the shelf registration and from equity compensation.